PRESS RELEASE
10 January 2017

BioInvent's collaboration partner ThromboGenics initiates Phase II study with the drug candidate THR-317

Lund, Sweden – 10 January 2017 – BioInvent International AB (OMXS: BINV) announces today that the company's collaboration partner ThromboGenics NV reports that the first patients have been enrolled in a study with the drug candidate THR-317 for the treatment of diabetic macular oedema. The study evaluates safety and efficacy of two dose levels of THR-317 and plans to include a total of 50 patients over a period of 12 months. The first results are expected during the first quarter of 2018.

BioInvent's ownership in THR-317 amounts to 40 percent provided the company contributes with half of historical and future development costs. As earlier communicated, BioInvent has initiated an evaluation of how to ensure that the value of the project for the company is optimized.

The clinical development of THR-317 is done by ThromboGenics. For further information, BioInvent therefore refers to the press release made by ThromboGenics on 10 January 2017, see www.thrombogenics.com.

Notes to editors:

About BioInvent
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia and TB-403, in cooperation with Oncurious, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. In December 2016, the Company signed a strategic research collaboration with Pfizer Inc. BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials.

For further information, please contact:
Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)707 16 89 30
michael.oredsson@bioinvent.com

Citigate Dewe Rogerson
David Dible/Katja Stout/ Marine Perrier
+44 (0)20 7638 9571
katja.stout@citigatedr.co.uk

BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 5.40 p.m. CET, on 10 January, 2017.